Zhengye Biotechnology Holding (ZYBT) Current Deferred Revenue (2023 - 2025)

Zhengye Biotechnology Holding (ZYBT) has reported Current Deferred Revenue for 3 consecutive years, with $669996.8 the latest figure, recorded in Q4 2025.

• On a quarterly basis, Current Deferred Revenue rose 38.1% year-over-year to $669996.8 in Q4 2025; TTM through Dec 2025 was $669996.8, a 38.1% increase from a year earlier, with the FY2025 full-year figure at $680000.0, up 42.56% from the prior year.
• Current Deferred Revenue was $669996.8 for Q4 2025 at Zhengye Biotechnology Holding, down from $698000.0 in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $698000.0 in Q2 2025 and troughed at $485166.8 in Q4 2024.
• A 3-year average of $598185.3 and a median of $604787.2 in 2023 frame the typical range for Current Deferred Revenue.
• Across the five-year window, Current Deferred Revenue fell 10.08% in 2024 and soared 38.1% in 2025, its largest moves.
• Over 3 years, Current Deferred Revenue stood at $539577.5 in 2023, then declined by 10.08% to $485166.8 in 2024, then soared by 38.1% to $669996.8 in 2025.
• The last three Current Deferred Revenue figures came in at $669996.8 (Q4 2025), $698000.0 (Q2 2025), and $485166.8 (Q4 2024), per Business Quant data.